<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39358724</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>03</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>05</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1479-5876</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>02</Day></PubDate></JournalIssue><Title>Journal of translational medicine</Title><ISOAbbreviation>J Transl Med</ISOAbbreviation></Journal><ArticleTitle>Explore genetic susceptibility association between viral infections and Guillain-Barré syndrome risk using two-sample Mendelian randomization.</ArticleTitle><Pagination><StartPage>890</StartPage><MedlinePgn>890</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">890</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12967-024-05704-8</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Numerous observational studies have indicated that patients with Guillain-Barré syndrome (GBS) frequently had infections with various pathogens before the onset of the disease, particularly several viral infections. Some of these infections are linked to specific clinical and immunological subgroups of GBS, suggesting a potential correlation between viral infections and the development of GBS. However, observational studies have several limitations, including the presence of confounding factors.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">We explored the potential correlation between HIV, SARS-CoV-2, varicella-zoster virus, herpes simplex virus, Epstein-Barr virus, hepatitis B virus, and influenza virus with GBS using a two-sample Mendelian randomization approach. The data was derived from published summary statistics from genome-wide association studies (GWAS). After removing linkage disequilibrium, selecting strong instrumental variables and addressing confounding factors, we would conduct a two-sample Mendelian randomization analysis along with sensitivity testing and the MR-Steiger directional test.</AbstractText><AbstractText Label="RESULT" NlmCategory="RESULTS">HIV may have a causal association with GBS (IVW: p = 0.010, OR [95% CI] 1.240 [1.052-1.463]), while no such relationship exists with COVID-19 (IVW: p = 0.275, OR [95% CI] 0.831[0.596-1.159]), varicella (IVW: p = 0.543, OR [95% CI] 0.919 [0.701-1.206]), herpes zoster (IVW: p = 0.563, OR [95% CI] 0.941 [0.766-1.156]), HSV (IVW: p = 0.280, OR [95% CI] 1.244 [0.837-1.851]), EBV (IVW: p = 0.218, OR [95% CI] 0.883 [0.724-1.076]), HBV (IVW: p = 0.179, OR [95% CI] 1.072 [0.969-1.187]), or influenza virus (IVW: p = 0.917, OR [95% CI] 0.971 [0.553-1.703]). We did not find any abnormal SNPs, pleiotropy, or heterogeneity, nor is there any reverse causation.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Our study results indicate a causal relationship between HIV and GBS, providing new research directions for the etiology of GBS.</AbstractText><CopyrightInformation>© 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kong</LastName><ForeName>Qing-Xiang</ForeName><Initials>QX</Initials><AffiliationInfo><Affiliation>Institute of Neuroscience, School of Basic Medical Sciences, Chongqing Medical University, Chongqing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Zhao-Kun</ForeName><Initials>ZK</Initials><AffiliationInfo><Affiliation>Institute of Neuroscience, School of Basic Medical Sciences, Chongqing Medical University, Chongqing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Yan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Institute of Neuroscience, School of Basic Medical Sciences, Chongqing Medical University, Chongqing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Lu-Lu</ForeName><Initials>LL</Initials><AffiliationInfo><Affiliation>Institute of Neuroscience, School of Basic Medical Sciences, Chongqing Medical University, Chongqing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Yuan-Jie</ForeName><Initials>YJ</Initials><AffiliationInfo><Affiliation>Institute of Neuroscience, School of Basic Medical Sciences, Chongqing Medical University, Chongqing, China. liuyuanjie@cqmu.edu.cn.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Anatomy, Chongqing Medical University, Chongqing, China. liuyuanjie@cqmu.edu.cn.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Laboratory of Major Brain Disease and Aging Research (Ministry of Education), Chongqing Medical University, Chongqing, China. liuyuanjie@cqmu.edu.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lian</LastName><ForeName>Zhi-Yun</ForeName><Initials>ZY</Initials><AffiliationInfo><Affiliation>Department of Neurology, Chongqing Hospital of Traditional Chinese Medicine, Chongqing, China. lianzhiyun47@163.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>YYZX20180052</GrantID><Agency>Xinglin Scholars</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Transl Med</MedlineTA><NlmUniqueID>101190741</NlmUniqueID><ISSNLinking>1479-5876</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020275" MajorTopicYN="Y">Guillain-Barre Syndrome</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057182" MajorTopicYN="Y">Mendelian Randomization Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014777" MajorTopicYN="Y">Virus Diseases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="Y">Genetic Predisposition to Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055106" MajorTopicYN="Y">Genome-Wide Association Study</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020641" MajorTopicYN="N">Polymorphism, Single Nucleotide</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Genetic susceptibility</Keyword><Keyword MajorTopicYN="N">Guillain-Barré Syndrome</Keyword><Keyword MajorTopicYN="N">Mendelian randomization analysis</Keyword><Keyword MajorTopicYN="N">Viral Infections</Keyword></KeywordList><CoiStatement>The authors declare that they have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>3</Day><Hour>10</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>3</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>2</Day><Hour>23</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>2</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39358724</ArticleId><ArticleId IdType="pmc">PMC11446148</ArticleId><ArticleId IdType="doi">10.1186/s12967-024-05704-8</ArticleId><ArticleId IdType="pii">10.1186/s12967-024-05704-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>van den Berg B, Walgaard C, Drenthen J, Fokke C, Jacobs BC, van Doorn PA. Guillain-Barré syndrome: pathogenesis, diagnosis, treatment and prognosis. Nat Rev Neurol. 2014;10:469–82.</Citation><ArticleIdList><ArticleId IdType="pubmed">25023340</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuijf ML, Godschalk PC, Gilbert M, Endtz HP, Tio-Gillen AP, Ang CW, van Doorn PA, Jacobs BC. Origin of ganglioside complex antibodies in Guillain-Barré syndrome. J Neuroimmunol. 2007;188:69–73.</Citation><ArticleIdList><ArticleId IdType="pubmed">17604126</ArticleId></ArticleIdList></Reference><Reference><Citation>Sejvar JJ, Baughman AL, Wise M, Morgan OW. Population incidence of Guillain-Barré syndrome: a systematic review and meta-analysis. Neuroepidemiology. 2011;36:123–33.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5703046</ArticleId><ArticleId IdType="pubmed">21422765</ArticleId></ArticleIdList></Reference><Reference><Citation>Finsterer J. Triggers of Guillain-Barre syndrome: Campylobacter jejuni predominates. Int J Mol Sci. 2022; 23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9696744</ArticleId><ArticleId IdType="pubmed">36430700</ArticleId></ArticleIdList></Reference><Reference><Citation>Khanmohammadi S, Malekpour M, Jabbari P, Rezaei N. Genetic basis of Guillain-Barre syndrome. J Neuroimmunol. 2021;358:577651.</Citation><ArticleIdList><ArticleId IdType="pubmed">34246981</ArticleId></ArticleIdList></Reference><Reference><Citation>Bentley SA, Ahmad S, Kobeissy FH, Toklu HZ. Concomitant Guillain-Barre syndrome and COVID-19: a meta-analysis of cases. Medicina. 2022; 58.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9788175</ArticleId><ArticleId IdType="pubmed">36557036</ArticleId></ArticleIdList></Reference><Reference><Citation>Abu-Rumeileh S, Abdelhak A, Foschi M, Tumani H, Otto M. Guillain-Barre syndrome spectrum associated with COVID-19: an up-to-date systematic review of 73 cases. J Neurol. 2021;268:1133–70.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7445716</ArticleId><ArticleId IdType="pubmed">32840686</ArticleId></ArticleIdList></Reference><Reference><Citation>Keddie S, Pakpoor J, Mousele C, Pipis M, Machado PM, Foster M, Record CJ, Keh RYS, Fehmi J, Paterson RW, et al. Epidemiological and cohort study finds no association between COVID-19 and Guillain-Barre syndrome. Brain. 2021;144:682–93.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7799186</ArticleId><ArticleId IdType="pubmed">33313649</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Azorin D, Martinez-Pias E, Trigo J, Hernandez-Perez I, Valle-Penacoba G, Talavera B, Simon-Campo P, de Lera M, Chavarria-Miranda A, Lopez-Sanz C, et al. Neurological comorbidity is a predictor of death in Covid-19 disease: a cohort study on 576 patients. Front Neurol. 2020;11:781.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7358573</ArticleId><ArticleId IdType="pubmed">32733373</ArticleId></ArticleIdList></Reference><Reference><Citation>Gershon AA, Breuer J, Cohen JI, Cohrs RJ, Gershon MD, Gilden D, Grose C, Hambleton S, Kennedy PG, Oxman MN, et al. Varicella zoster virus infection. Nat Rev Dis Primers. 2015;1:15016.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5381807</ArticleId><ArticleId IdType="pubmed">27188665</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagel MA, Gilden DH. The protean neurologic manifestations of varicella-zoster virus infection. Cleve Clin J Med. 2007;74:489–94.</Citation><ArticleIdList><ArticleId IdType="pubmed">17682626</ArticleId></ArticleIdList></Reference><Reference><Citation>Nerabani Y, Atli AA, Hamdan O, Hajjar Mwaffak A, Haj Hammadh NAH, Marstawi H, Hora S, Alabd N. Guillain-Barre syndrome following varicella-zoster virus infection: a case report and systematic review. Ann Med Surg. 2023;85:5621–8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10617928</ArticleId><ArticleId IdType="pubmed">37915710</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith GD, Ebrahim S. “Mendelian randomization”: can genetic epidemiology contribute to understanding environmental determinants of disease? Int J Epidemiol. 2003;32:1–22.</Citation><ArticleIdList><ArticleId IdType="pubmed">12689998</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans DM, Davey Smith G. Mendelian randomization: new applications in the coming age of hypothesis-free causality. Annu Rev Genomics Hum Genet. 2015;16:327–50.</Citation><ArticleIdList><ArticleId IdType="pubmed">25939054</ArticleId></ArticleIdList></Reference><Reference><Citation>Kurki MI, Karjalainen J, Palta P, Sipilä TP, Kristiansson K, Donner KM, Reeve MP, Laivuori H, Aavikko M, Kaunisto MA, et al. FinnGen provides genetic insights from a well-phenotyped isolated population. Nature. 2023;613:508–18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9849126</ArticleId><ArticleId IdType="pubmed">36653562</ArticleId></ArticleIdList></Reference><Reference><Citation>Taquet MGJR, Husain M, Luciano S, Harrison PJ. The COVID-19 host genetics initiative, a global initiative to elucidate the role of host genetic factors in susceptibility and severity of the SARS-CoV-2 virus pandemic. Eur J Hum Genet. 2020;28:715–8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7220587</ArticleId><ArticleId IdType="pubmed">32404885</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakaue S, Kanai M, Tanigawa Y, Karjalainen J, Kurki M, Koshiba S, Narita A, Konuma T, Yamamoto K, Akiyama M, et al. A cross-population atlas of genetic associations for 220 human phenotypes. Nat Genet. 2021;53:1415–24.</Citation><ArticleIdList><ArticleId IdType="pubmed">34594039</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee K, Lim CY. Mendelian randomization analysis in observational epidemiology. J Lipid Atheroscler. 2019;8:67–77.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7379124</ArticleId><ArticleId IdType="pubmed">32821701</ArticleId></ArticleIdList></Reference><Reference><Citation>Pierce BL, Ahsan H, Vanderweele TJ. Power and instrument strength requirements for Mendelian randomization studies using multiple genetic variants. Int J Epidemiol. 2011;40:740–52.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3147064</ArticleId><ArticleId IdType="pubmed">20813862</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid instruments: effect estimation and bias detection through egger regression. Int J Epidemiol. 2015;44:512–25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4469799</ArticleId><ArticleId IdType="pubmed">26050253</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowden J, Davey Smith G, Haycock PC, Burgess S. Consistent estimation in Mendelian randomization with some invalid instruments using a weighted median estimator. Genet Epidemiol. 2016;40:304–14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4849733</ArticleId><ArticleId IdType="pubmed">27061298</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartwig FP, Davey Smith G, Bowden J. Robust inference in summary data Mendelian randomization via the zero modal pleiotropy assumption. Int J Epidemiol. 2017;46:1985–98.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5837715</ArticleId><ArticleId IdType="pubmed">29040600</ArticleId></ArticleIdList></Reference><Reference><Citation>Burgess S, Butterworth A, Thompson SG. Mendelian randomization analysis with multiple genetic variants using summarized data. Genet Epidemiol. 2013;37:658–65.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4377079</ArticleId><ArticleId IdType="pubmed">24114802</ArticleId></ArticleIdList></Reference><Reference><Citation>Verbanck M, Chen CY, Neale B, Do R. Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases. Nat Genet. 2018;50:693–8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6083837</ArticleId><ArticleId IdType="pubmed">29686387</ArticleId></ArticleIdList></Reference><Reference><Citation>Bar-Joseph G, Etzioni A, Hemli J, Gershoni-Baruch R. Guillain-Barre syndrome in three siblings less than 2 years old. Arch Dis Child. 1991;66:1078–9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1793037</ArticleId><ArticleId IdType="pubmed">1929520</ArticleId></ArticleIdList></Reference><Reference><Citation>Geleijns K, Brouwer BA, Jacobs BC, Houwing-Duistermaat JJ, van Duijn CM, van Doorn PA. The occurrence of Guillain-Barre syndrome within families. Neurology. 2004;63:1747–50.</Citation><ArticleIdList><ArticleId IdType="pubmed">15534275</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L, Wang FS, Gershwin ME. Human autoimmune diseases: a comprehensive update. J Intern Med. 2015;278:369–95.</Citation><ArticleIdList><ArticleId IdType="pubmed">26212387</ArticleId></ArticleIdList></Reference><Reference><Citation>de Castro G, Bastos PG, Martinez R, de Castro Figueiredo JF. Episodes of Guillain-Barré syndrome associated with the acute phase of HIV-1 infection and with recurrence of viremia. Arq Neuropsiquiatr. 2006;64:606–8.</Citation><ArticleIdList><ArticleId IdType="pubmed">17119803</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishijima T, Tsukada K, Takeuchi S, Chiba A, Honda M, Teruya K, Gatanaga H, Kikuchi Y, Oka S. Antiretroviral therapy for treatment-naïve chronic HIV-1 infection with an axonal variant of Guillain-Barré syndrome positive for anti-ganglioside antibody: a case report. Intern Med. 2011;50:2427–9.</Citation><ArticleIdList><ArticleId IdType="pubmed">22001481</ArticleId></ArticleIdList></Reference><Reference><Citation>Zandman-Goddard G, Shoenfeld Y. HIV and autoimmunity. Autoimmun Rev. 2002;1:329–37.</Citation><ArticleIdList><ArticleId IdType="pubmed">12848988</ArticleId></ArticleIdList></Reference><Reference><Citation>Tao Y, Zhang X, Markovic-Plese S. Toll-like receptor (TLR)7 and TLR9 agonists enhance interferon (IFN) beta-1a’s immunoregulatory effects on B cells in patients with relapsing-remitting multiple sclerosis (RRMS). J Neuroimmunol. 2016;298:181–8.</Citation><ArticleIdList><ArticleId IdType="pubmed">27609294</ArticleId></ArticleIdList></Reference><Reference><Citation>Urban C, Zychlinsky A. Netting bacteria in sepsis. Nat Med. 2007;13:403–4.</Citation><ArticleIdList><ArticleId IdType="pubmed">17415369</ArticleId></ArticleIdList></Reference><Reference><Citation>Vidal JE, Guedes BF, Gomes HR, Mendonca RH. Guillain-Barre syndrome spectrum as manifestation of HIV-related immune reconstitution inflammatory syndrome: case report and literature review. Braz J Infect Dis. 2022;26:102368.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9387489</ArticleId><ArticleId IdType="pubmed">35605654</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopes M, Marques P, Silva B, Cruz G, Serra JE, Ferreira E, Alves H, da Cunha JS. Guillain-Barre syndrome as the first presentation of human immunodeficiency virus infection. BMC Neurol. 2021;21:321.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8371896</ArticleId><ArticleId IdType="pubmed">34407758</ArticleId></ArticleIdList></Reference><Reference><Citation>Pelea T, Reuter U, Schmidt C, Laubinger R, Siegmund R, Walther BW. SARS-CoV-2 associated Guillain-Barre syndrome. J Neurol. 2021;268:1191–4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7414629</ArticleId><ArticleId IdType="pubmed">32770414</ArticleId></ArticleIdList></Reference><Reference><Citation>Toscano G, Palmerini F, Ravaglia S, Ruiz L, Invernizzi P, Cuzzoni MG, Franciotta D, Baldanti F, Daturi R, Postorino P, et al. Guillain-Barre syndrome associated with SARS-CoV-2. N Engl J Med. 2020;382:2574–6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7182017</ArticleId><ArticleId IdType="pubmed">32302082</ArticleId></ArticleIdList></Reference><Reference><Citation>Bigaut K, Mallaret M, Baloglu S, Nemoz B, Morand P, Baicry F, Godon A, Voulleminot P, Kremer L, Chanson JB, de Seze J. Guillain-Barre syndrome related to SARS-CoV-2 infection. Neurol Neuroimmunol Neuroinflamm. 2020; 7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7286648</ArticleId><ArticleId IdType="pubmed">32461235</ArticleId></ArticleIdList></Reference><Reference><Citation>Latov N. Campylobacter jejuni infection, anti-ganglioside antibodies, and neuropathy. Microorganisms. 2022; 10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9695184</ArticleId><ArticleId IdType="pubmed">36363731</ArticleId></ArticleIdList></Reference><Reference><Citation>Lucchese G, Floel A. Molecular mimicry between SARS-CoV-2 and respiratory pacemaker neurons. Autoimmun Rev. 2020;19:102556.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7252083</ArticleId><ArticleId IdType="pubmed">32361194</ArticleId></ArticleIdList></Reference><Reference><Citation>Hadden RD, Karch H, Hartung HP, Zielasek J, Weissbrich B, Schubert J, Weishaupt A, Cornblath DR, Swan AV, Hughes RA, et al. Preceding infections, immune factors, and outcome in Guillain-Barre syndrome. Neurology. 2001;56:758–65.</Citation><ArticleIdList><ArticleId IdType="pubmed">11274311</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>